12954 Federal Register / Vol. 86, No. 42 / Friday, March 5, 2021 / Notices 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

Activity 

Number 

of 

respondents 

Number 

of responses 

per 

respondent 

Total annual 

responses 

Average burden 

per response Total hours 

Screener .............................................................. 485,580 1 485,580 0.083 (5 minutes) ........... 40,465 

Self-Administered Surveys .................................. 133,728 1 133,728 0.33 (20 minutes) ........... 44,576 

Total ............................................................. ........................ ........................ ........................ ........................................ 85,041 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

Number of respondents to be included 

in each new survey will vary, 

depending on the nature of the material 

or message being tested and the target 

audience. Table 1 provides examples of 

the types of activities that may be 

administered and estimated burden 

levels during the 3-year period. Time to 

read, review, or complete the activity is 

built into the ‘‘Average Burden per 

Response’’ figures. Our estimated 

burden for the information collection 

reflects an overall increase of 60,000 

hours and a corresponding increase of 

461,808 responses. We attribute the 

adjustment to an increase in the number 

of new quantitative studies that are 

anticipated underneath this information 

collection during the next 3 years 

(proposed extension). 

Dated: March 1, 2021. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2021–04606 Filed 3–4–21; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2012–P–1189] 

Canned Tuna Deviating From the 

Standard of Identity; Amendment of 

Temporary Marketing Permit 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or we) is 

amending StarKist Seafood Company’s 

temporary permit to market test canned 

tuna. The temporary permit is amended 

to add three additional manufacturing 

locations and to increase the amount of 

test product. This amendment will 

allow the applicant to continue to test 

market the test product and collect data 

on consumer acceptance of the test 

product. 

FOR FURTHER INFORMATION CONTACT: 

Marjan Morravej, Center for Food Safety 

and Applied Nutrition (HFS–820), Food 

and Drug Administration, 5001 Campus 

Dr., College Park, MD 20740, 240–402– 

2371. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of June 20, 2014 (79 FR 

35362), we issued a notice announcing 

that we had issued a temporary permit 

to StarKist Seafood Company, 225 North 

Shore Dr., Pittsburgh, PA 15212, to 

market test products identified as 

canned tuna products. The permit 

allowed for the test product to be 

manufactured at Galapesca S.A., Km. 

12.5 Via A Duale, Guayaquil, Ecuador, 

and StarKist Samoa Co., 368 Atu’u Rd., 

Pago Pago, American Samoa 96799. We 

issued the permit to facilitate market 

testing of products that deviate from the 

requirements of the standard of identity 

for canned tuna in 21 CFR 161.190, 

which was issued under section 401 of 

the Federal Food, Drug, and Cosmetic 

Act (21 U.S.C. 341). 

In the Federal Register of March 7, 

2016 (81 FR 11813), we issued a notice 

announcing that we were extending the 

temporary market permit issued to 

StarKist Seafood Company. The 

extension allows the applicants to 

continue to measure consumer 

acceptance of the products and assess 

the commercial feasibility of the 

products, in support of a petition to 

amend the standard of identity for 

canned tuna. The new expiration date of 

the permit will be either the effective 

date of a final rule amending the 

standard of identity for canned tuna that 

may result from the petition or 30 days 

after denial of the petition. 

Under our regulations at 21 CFR 

130.17(f), we are amending the 

temporary permit issued to StarKist 

Seafood Company, to allow the test 

product to be manufactured at three 

additional plants: Tropical Canning 

(Thailand) Public Co., LTD., 1⁄1 M.2 

T.Thungyai, Hatyai, Songkhla 90110, 

Thailand; ISA Value Co., Ltd., 44/4 

Moo1, Petchkasem Road, Yaicha, 

Sampran, Nakornpathom 73110, 

Thailand; and Tri-Marine (Solomon 

Islands), Soltuna Ltd., 1 Tuna Dr., Noro, 

Western Province, Solomon Islands. We 

are also amending the temporary permit 

to increase the amount of test product 

to be market tested to 213,500,000 

pounds (96,841,971 kilograms) in retail 

cans of various sizes. All other 

conditions and terms of this permit 

remain the same. 

Dated: February 26, 2021. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2021–04607 Filed 3–4–21; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the COVID–19 Health Equity 

Task Force 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice of meeting. 

SUMMARY: As required by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that the COVID–19 Health Equity Task 

Force (Task Force) will hold a virtual 

meeting on March 26, 2021. The 

purpose of this meeting is to discuss 

equitable vaccine access and 

acceptance. This meeting is open to the 

public and will be live-streamed at 

www.hhs.gov/live. Information about the 

meeting will be posted on the HHS 

Office of Minority Health website: 

www.minorityhealth.hhs.gov/ 

healthequitytaskforce/ prior to the 

meeting. 

DATES: The Task Force meeting will be 

held on Friday, March 26, 2021, from 

approximately 12 p.m. to 3 p.m. ET 

(times are tentative and subject to 

change). The confirmed time and 

agenda will be posted on the COVID–19 

Health Equity Task Force website: 

www.minorityhealth.hhs.gov/ 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 42 / Friday, March 5, 2021 / Notices 12955 

healthequitytaskforce/ when this 

information becomes available. 

FOR FURTHER INFORMATION CONTACT: 

Samuel Wu, Designated Federal Officer 

for the Task Force; Office of Minority 

Health, Department of Health and 

Human Services, Tower Building, 1101 

Wootton Parkway, Suite 100, Rockville, 

Maryland 20852. 

Phone: 240–453–6173; email: 

COVID19HETF@hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background: COVID–19 Health Equity 

Task Force (Task Force) was established 

by Executive Order 13995, dated 

January 21, 2021. The Task Force is 

tasked with developing a set of 

recommendations to the President, 

through the Coordinator of the COVID– 

19 Response and Counselor to the 

President (COVID–19 Response 

Coordinator) for mitigating the health 

inequities caused or exacerbated by the 

COVID–19 pandemic and for preventing 

such inequities in the future. The Task 

Force shall submit a final report to the 

COVID–19 Response Coordinator 

addressing any ongoing health 

inequities faced by COVID–19 survivors 

that may merit a public health response, 

describing the factors that contributed to 

disparities in COVID–19 outcomes, and 

recommending actions to combat such 

disparities in future pandemic 

responses. 

The meeting is open to the public and 

will be live-streamed at www.hhs.gov/ 

live. A public comment session will be 

held during the meeting. Pre-registration 

is required to provide public comment 

during the meeting. To pre-register to 

attend or to provide public comment, 

please send an email to 

COVID19HETF@hhs.gov and include 

your name, title, and organization by 

close of business on Friday, March 19, 

2021. Comments will be limited to no 

more than three minutes per speaker 

and should be pertinent to the meeting 

discussion. Individuals are encouraged 

to provide a written statement of any 

public comment(s) for accurate minutetaking purposes. If you decide you 

would like to provide public comment 

but do not pre-register, you may submit 

your written statement by emailing 

COVID19HETF@hhs.gov no later than 

close of business Thursday, April 1, 

2021. Individuals who plan to attend 

and need special assistance, such as 

sign language interpretation or other 

reasonable accommodations, should 

contact: COVID19HETF@hhs.gov and 

reference this meeting. Requests for 

special accommodations should be 

made at least ten (10) business days 

prior to the meeting. 

Dated: March 1, 2021. 

Samuel Wu, 

Designated Federal Officer, COVID–19 Health 

Equity Task Force. 

[FR Doc. 2021–04605 Filed 3–4–21; 8:45 am] 

BILLING CODE 4150–29–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Career Development Program to Promote 

Diversity in Health Research (K01). 

Date: April 1, 2021. 

Time: 9:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Lindsay M. Garvin, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Suite 208–Y, 

Bethesda, MD 20892, (301) 827–7911, 

lindsay.garvin@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: March 1, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–04523 Filed 3–4–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA Panel: 

Co-Occurring Conditions, Data Science, and 

Clinical Trials Readiness in Down Syndrome. 

Date: March 25, 2021. 

Time: 9:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Maribeth Champoux, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3170, 

MSC 7848, Bethesda, MD 20892, 301–594– 

3163, champoum@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR 19–386 

Environmental Risks for Psychiatric 

Disorders: Biological Basis of 

Pathophysiology. 

Date: March 25, 2021. 

Time: 3:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Julius Cinque, MS, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5186, 

MSC 7846, Bethesda, MD 20892, (301) 435– 

1252, cinquej@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Mechanisms of Stress, Emotion, 

Health and Reward. 

Date: March 26, 2021. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Telephone Conference 

Call). 

Contact Person: Andrea B Kelly, Ph.D., 

Scientific Review Officer, Center for 


jbell on DSKJLSW7X2PROD with NOTICES